However, the long-term response observed for a proportion of patients undergoing PD-1 blockade appears to contradict these findings, but there might be alternative explanations such as reinvigoration of certain T-cell subsets [33, 34], recruitment of new T-cells into the tumor site [35], or even differences in microbiota [36]. The gene discussed is PDCD1; the disease is neoplasm.